Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Share Cafe Micro/Small Cap "Hidden Gems" Webinar (August 2021)
13 slides from Genetic Signatures's conference presentation, Aug 13, 2021
Slide 1: Investor Webinar Presentation
ASX Announcement 13 August 2021 Investor Webinar Presentation Genetic Signatures Limited (ASX: GSS) (“Genetic Signatures” or “the Company”) is pleased to announce its participation in the Share Cafe Webinar - Micro/Small Cap "Hidden Gems" Webinar to be held today (Friday 13 August 2021) from 12:30pm
Slide 2: Company Presentation
“Driving better healthcare through innovation” Using 3baseTM technology to improve syndromic screening. Company Presentation August 2021 1
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and comprises written materials/slides for a verbal presentation concerning the Company and should be read in that context. This presentation is proprietary to GSS. It may not be reprodu
Slide 4: Executive Summary
Executive Summary The Company Solid history of growth ‒ Founded 20 years ago, by Geoff Grigg, ex ‒ YoY growth since listing Divisional Head, CSIRO biomolecular ‒ 4 year CAGR – 93% (2018-2021) engineering ‒ 151% increase in sales FY21 vs FY20 ‒ ASX listed Molecular Diagnostics Company, ‒ Instrument i
Slide 5: Trusted & Proven Technology
Trusted & Proven Technology A ‘Syndromic Screening’ approach allows users to test a broad range of clinically relevant pathogens based on patient symptoms, helping clinicians make an accurate diagnosis • Streamlined universal sample processing kits linked to highly multiplexed real- time PCR screeni
Slide 6: 3base Technology
3baseTM Technology The 3base™ genome is less susceptible to mutations Cytosine (C) is the most unstable of the 4bases • It spontaneously deaminates to Uracil (U) and ultimately Thymine (T) in DNA • This rate is some 140-fold higher in single- stranded molecules (eg ssRNA viruses such as SARS-CoV-2)
Slide 7: 12 Months in Review
12 Months in Review September 2020 Record quarterly revenue up 585% on pcp December 2020 Supply agreement with Boston Medical Center – 1st US customer December 2020 Quarterly revenue up 744% on pcp January 2021 CE-IVD received for EasyScreenTM STI Genital Pathogen Detection Kit March 2021 Quarterly
Slide 8: Continued Strong Revenue Growth
Continued Strong Revenue Growth Increasing contribution from international business Quarterly revenue from sales (A$m) • Record sales of $28.3m in FY21, 2.5 times 28.3 FY20 sales 5.4 • International sales represent 21% of revenue, up from 10% in FY20 4.2 • Strong demand for tests continue due to ong
Slide 9: Regional Summary
Regional Summary Focus on securing long-term customer contracts with high throughput pathology groups, hospitals and government run programs North America EMEA Australia/NZ • Direct sales in USA, sales & • Direct sales in Germany and UK, • Sales & support in Australia; support teams in place distrib
Slide 10: FDA Approvals Program
FDA Approvals Program iteric Protozoan M t Dynamics Est. 5.5m Enteric Protozoan tests p.a in the US Initial focus on largest 30 “high throughput” centralised labs Smaller decentralised labs more accessible with development of new testing hardware Whilst awaiting clearance, GSS can sell “parts/ingred
Slide 11: EasyScreen Product Portfolio
EasyScreenTM Product Portfolio * *FDA for protozoa underway
Slide 12: Looking Forward
Looking Forward Multiple growth opportunities Focus on long-term customer contracts & customer satisfaction • Secure long-term customer contracts with high throughput pathology groups, hospitals and government run programs • Provide reliable quality customer service to build strong relationships Lev
Slide 13: Contact us
Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media 12
Genetic Signatures — Share Cafe Micro/Small Cap "Hidden Gems" Webinar (August 2021) on 6ix